Welcome to our dedicated page for Hydromer news (Ticker: HYDI), a resource for investors and traders seeking the latest updates and insights on Hydromer stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Hydromer's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Hydromer's position in the market.
Summary not available.
Hydromer Inc. (OTC: HYDI) has appointed Mr. Michael E. Torti as its new Chief Executive Officer, effective April 25, 2023. Previously the Vice President of Sales, Marketing, and Global Business Development, Torti brings over 30 years of experience in the manufacturing sector, enhancing the company’s leadership with his proven track record in sales and market development. The Board expressed confidence in Torti's vision, believing it will lead to future success. Hydromer is a global supplier of specialty coatings and biopolymers mainly for medical devices and industrial applications, committed to innovation and quality, as evidenced by its numerous patents and certifications in production and quality standards.
Hydromer, Inc. (HYDI) has announced the removal of Peter von Dyck as CEO, effective March 24, 2023. This decision follows a vote by the Board of Directors as part of a broader corporate restructuring aimed at improving the company's economic and financial position. Von Dyck, who held the CEO position since September 2018, led Hydromer through significant challenges, including the COVID-19 pandemic. Currently, the Board has opted to keep the CEO position vacant while they seek a suitable successor. Hydromer specializes in surface modification and coating solutions, providing services across various industries globally.
Hydromer (OTC: HYDI) has appointed Michael Torti as the new Vice President of Global Sales, Marketing, and Business Development, effective January 9, 2023. Torti brings over 30 years of experience in B2B sales and marketing of medical devices and complex manufactured goods. Previously, he held key roles in various companies, demonstrating expertise in revenue growth and market development. CEO Peter M. von Dyck expressed confidence in Torti's ability to drive sales and expand Hydromer's presence in the medical device and industrial markets.
Hydromer, Inc. (HYDI:OTC) has appointed Cam Cruickshank, Ph.D., to its Board of Directors, replacing long-serving member Dieter Heineman. Cruickshank, currently the President of Cabarrus College of Health Sciences, brings over 15 years of executive experience and strong financial expertise. His background includes roles in budget management and strategic development across various institutions. The company values his healthcare insights as it continues to innovate in medical device surface modifications.
Hydromer, Inc. (HYDI:OTC) announces the appointment of Cortney Wells as Director of Finance, reporting to CEO Peter M. von Dyck. With over 12 years of finance experience, her expertise includes SEC regulations and US/UK GAAP compliance. Wells previously served as Global Controller at Safeguard Medical and has held various finance roles across industries. The management believes her skills will enhance Hydromer’s market presence and ensure robust financial controls, supporting the company's commitment to innovation and service in surface modification.
Hydromer, Inc. (HYDI:OTC) announces the operational launch of its new facility in Concord, NC, enhancing capabilities in medical coatings and industrial applications. This FDA-certified site features advanced R&D and production services, including custom coatings and extensive testing facilities. The new modular ISO-class 8 clean room can accommodate devices up to 20-FT in length. With over 400 patents and 40 years of innovation, Hydromer plans to meet growing global demand, especially in infection control technologies, as highlighted by CEO Peter M. von Dyck.
Hydromer, Inc. (HYDI:OTC) has appointed Mr. Craig Hughes as the new Global Business Development Manager. With a Ph.D. in Organic Chemistry and significant experience in the chemical industry, Hughes brings expertise from previous roles at EMD Performance Materials and other notable companies. His addition is expected to enhance Hydromer's strategy in the specialty polymer and surface coatings market, particularly in medical and healthcare applications. The company is ISO certified and focuses on hydrophilic polymer-based coatings.
Hydromer (HYDI:OTC) has been selected as the key coatings partner for Avinger, focusing on innovations in catheter-based systems for Peripheral Artery Disease (PAD). Avinger’s products utilizing Hydromer’s coatings include Pantheris®, Ocelot, and the new Tigereye™ device, enhancing performance by enabling safer and more effective treatments. Hydromer’s hydrophilic coatings are recognized as critical in advancing Avinger’s medical technologies, improving patient outcomes through reduced risk of arterial injury.